Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2010

View Archived Issues

Bristol-Myers Squibb claims new lysophospholipid S1P1 receptor agonists

Abbott discloses new calcium channel blockers

Takeda discovers new PARP inhibitors

Incyte presents new tyrosine kinase inhibitors

Intellikine claims new PI3K and mTOR inhibitors

Merck KGaA discloses new MetAP 2 inhibitors

Riluzole exhibits cardioprotective activity in vivo

Alectos and Merck & Co. to codevelop O-GlcNAcase modulators for AD

FDA approves ella tablets for emergency contraception

LIPO-102 reduces abdominal fat in phase IIa study

Siltuximab shows promise in phase I trial in Castleman's disease

U.S. scientists describe new magnetic nanoparticles for multimodal imaging

Avasimibe reduces beta-amyloid burden in model of Alzheimer's disease

Briakinumab is safe and efficacious in phase II and III trials in psoriasis

Biofrontera obtains manufacturing and distribution license for pharma products

LifeCycle Pharma to conduct phase III LCP-Tacro trial in de novo kidney transplantation

NIDA awards grant to Selecta Biosciences for nicotine vaccine development

Antiherpes nanoviricides are efficacious in cell culture

Green Cross obtains marketing approval for peramivir in South Korea

US WorldMeds acquires Solstice Neurosciences

NextWave and Tris Pharma to collaborate on CNS drug development

ValiRx to develop CRT's prostate cancer candidate VAL-201

FDA proposes to withdraw marketing approval for midodrine hydrochloride

MMV contributes patents to support neglected tropical disease research

Morphotek begins phase I MORAb-028 trial in advanced melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...